Get the Stockscreener App
0.5408
1.12%
0.006
After Hours:
.54
-0.0008
-0.15%
Allovir Inc stock is traded at $0.5408, with a volume of 98,890.
It is up +1.12% in the last 24 hours and down -32.65% over the past month.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
See More
Previous Close:
$0.5348
Open:
$0.525
24h Volume:
98,890
Relative Volume:
0.34
Market Cap:
$59.50M
Revenue:
-
Net Income/Loss:
$-168.86M
P/E Ratio:
-0.3021
EPS:
-1.79
Net Cash Flow:
$-125.29M
1W Performance:
-5.14%
1M Performance:
-32.65%
6M Performance:
-28.56%
1Y Performance:
-64.88%
1-Day Range:
$0.515
$0.55
1-Week Range:
$0.51
$0.5996
52-Week Range:
$0.51
$2.485
Allovir Inc Stock (ALVR) Company Profile
Name
Allovir Inc
Sector
Industry
Phone
(617) 433-2605
Address
1100 WINTER STREET, WALTHAM
Compare ALVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.5408 | 59.50M | 0 | -168.86M | -125.29M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-26-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-22-23 | Downgrade | JP Morgan | Overweight → Underweight |
| Dec-22-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-18-23 | Initiated | BofA Securities | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | JP Morgan | Overweight |
| Aug-24-20 | Initiated | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | SVB Leerink | Outperform |
View All
Allovir Inc Stock (ALVR) Latest News
Allovir stock plunges to 52-week low, touches $0.51 By Investing.com - Investing.com Canada
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Allovir stock plunges to 52-week low, touches $0.51 - Investing.com
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of INSI, LBRDA, ROIC and ALVR - The Malaysian Reserve
Finansavisen - Finansavisen
AlloVir falls after all-stock merger deal with Kalaris - MSN
AlloVir to combine with Kalaris Therapeutics in all-stock transaction - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investo - GuruFocus.com
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of IPXX, YOTA, IVCP and ALVR - GlobeNewswire Inc.
AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Drop in Short Interest - MarketBeat
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BSA bureau
Allovir stock plunges to 52-week low of $0.58 amid market challenges - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - cnhinews.com
$hareholder Alert: The M&A Class Action Firm Launches Legal Inquiry the Merger ROIC, VINE, ALVR and CDMO - AccessWire
AlloVir and Kalaris enter merger to advance retinal disease therapies - Pharmaceutical Technology
AlloVir and Kalaris Therapeutics Announce Merger - FinSMEs
$hareholder Alert: The M&A Class Action Launches Legal Inquiry for the Merger of ROIC, VINE, ALVR and CDMO - AccessWire
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders - GlobeNewswire
ROIC, VINE, ALVR and CDMO Alert: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Items Tagged with 'TH-103' - BioWorld Online
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger - BioCentury
Items Tagged with 'Kalaris Therapeutics Inc.' - BioWorld Online
Allovir sees a new direction with Kalaris merger - BioWorld Online
SEC Form 425 filed by AlloVir Inc. - Quantisnow
Kalaris to go public via reverse merger with AlloVir - BioPharma Dive
AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
AlloVir and Kalaris Merge to Advance Retinal Therapies - TipRanks
AlloVir and Kalaris Therapeutics To Merge - citybiz
AlloVir Shares Slide Premarket on Reverse Merger With Kalaris Therapeutics - MarketWatch
AlloVir stock falls after Kalaris merger deal (ALVR:NASDAQ) - Seeking Alpha
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina - The Manila Times
AlloVir and Kalaris Therapeutics Announce Agreement for - GlobeNewswire
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.05% - MSN
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact The Gross Law Firm - GuruFocus.com
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks - Simply Wall St
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Joi - GuruFocus.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely - Simply Wall St
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to - GuruFocus.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Invest - GuruFocus.com
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James - GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) - GuruFocus.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Allovir Inc Stock (ALVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):